Compare Boston Scientific Corporation (BSX) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Gigacloud Technology Inc — how do they compare? Boston Scientific Corporation trades at $42.51 (market cap $66.37B), while Gigacloud Technology Inc trades at $35.78 (market cap $1.32B). The key difference: Boston Scientific Corporation is far larger — about 50.3× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | GCT | |
|---|---|---|
Market Cap | $66.37B | $1.32B |
Sector | Health | Technology |
52-Week High | $108.14 | $51.80 |
52-Week Low | $42.63 | $20.26 |
Enterprise Value | $75.94B | $1.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
GigaCloud Technology (GCT) trades at $35.40, up 2.88% today, showing strong momentum with consistent earnings beats and robust fundamentals. The stock exhibits a bullish technical signal with key resistance at $36 and support at $34. Recent financials reveal impressive profitability with a 10.77% net income margin and 32.14% ROE, while valuation ratios like P/E of 8.96 suggest potential undervaluation. Positive media coverage highlights growth prospects, including recognition as a 'World Growth Leader' by TIME in June 2026.
Outlook remains positive due to earnings growth and operational efficiency, but risks include market volatility and competitive pressures. Analyst consensus is bullish with 67% buy ratings, supporting upside potential if execution continues. Investors should weigh strong cash flow against sector-specific headwinds for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
